DiaMedica Therapeutics Inc. Common Stock/$DMAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Ticker
$DMAC
Sector
Primary listing
Employees
35
Headquarters
Website
DMAC Metrics
BasicAdvanced
$307m
-
-$0.71
1.00
-
Price and volume
Market cap
$307m
Beta
1
52-week high
$10.42
52-week low
$3.48
Average daily volume
171k
Financial strength
Current ratio
9.11
Quick ratio
8.983
Long term debt to equity
0.205
Total debt to equity
0.449
Profitability
EBITDA (TTM)
-36.692
Effective tax rate (TTM)
-0.08%
Management effectiveness
Return on assets (TTM)
-49.96%
Return on equity (TTM)
-86.47%
Valuation
Price to book
6.49
Price to tangible book (TTM)
6.49
Price to free cash flow (TTM)
-9.117
Free cash flow yield (TTM)
-10.97%
Free cash flow per share (TTM)
-0.624
Growth
Earnings per share change (TTM)
8.84%
3-year earnings per share growth (CAGR)
6.54%
10-year earnings per share growth (CAGR)
6.29%
What the Analysts think about DMAC
Analyst ratings (Buy, Hold, Sell) for DiaMedica Therapeutics Inc. Common Stock stock.
DMAC Financial Performance
Revenues and expenses
DMAC Earnings Performance
Company profitability
DMAC News
AllArticlesVideos
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
Business Wire·2 days ago
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
Business Wire·3 weeks ago
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs